Eisai President Looking To Acquire Generics Maker
This article was originally published in PharmAsia News
Eisai is looking for a generics drug maker to acquire in an effort to build its position in the markets developing in emerging countries, President Harua Naito says. Naito said in an interview his company considers the business of generic drugs as different from that of making innovative drugs, so it would be difficult for Eisai to make the switch on its own. The company's newly opened European Knowledge Center in London affords Eisai the capacity to carry out all aspects of the drug business in a third location, in addition to current operations in Japan and the United States. (Click here for more - a subscription may be required
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.